U.S. License Holder:
Allocord
Date of License:
May-30-2013
Last Update:
Dec-15-2024
FDA-Approved Indications
ALLOCORD (HPC, Cord Blood) is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated donor hematopoietic progenitor cell transplantation procedures in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.